The prime minister has said he will be getting his coronavirus vaccination "very shortly".
"It will certainly be Oxford-AstraZeneca that I will be having," Mr Johnson told the Commons.
The PM was asked to comment on the decision of more than a dozen EU countries to suspend use of the Oxford-AstraZeneca jab after reports of some people suffering blood clots after being vaccinated.
The European Medicines Agency (EMA) has said it will conduct a full scientific review of the jab, but said it "remains convinced" that the benefits of having it outweigh the risk.
It said the number of thromboembolic events (blood clots) in people inoculated does not seem higher than among the general population.
The EMA added that as of 10 March, a total of 30 cases of blood clotting had been reported among almost five million people vaccinated with the AstraZeneca shot in the European Economic Area, which links 30 European countries.
The World Health Organisation is also looking into the reports of blood clots, but said it still believed the benefits outweigh the risk.
Professor Andrew Pollard, director of the Oxford group that developed the vaccine, said there is "very reassuring evidence there is no increase in a blood clot phenomenon here in the UK, where most of the doses in Europe have been given so far".
AstraZeneca has said there is no cause for concern, adding that it had conducted a review covering more than 17 million people vaccinated in the EU and the UK which had shown no evidence of an increased risk of blood clots.